Hofseth Biocare ASA: PRIMARY INSIDER NOTIFICATION
Hofseth BioCare ASA (HBC) · publisert 28. februar 2023 kl. 08:00 · vis på NewsWeb
Transaksjoner
| Person | Rolle | Type | Volum | Pris | Dato | ISIN | Handelsplass |
|---|---|---|---|---|---|---|---|
| Chief Scientific via Bomi Framroze Holding AS | – | Kjøp | 200 000 | 2,69 NOK | 27. februar 2023 | – | Outside a trading venue |
Vedlegg
- PDMR notification form - Bomi Framroze Holding AS.pdf (application/pdf, originaldokument)
Meldingstekst
Bomi Framroze Holding AS, a close associate of primary insider and Chief
Scientific Officer Dr. Bomi Framroze in Hofseth Biocare ASA ("HBC"), has on 27
February 2023 purchased 200,000 shares in HBC at a price of NOK 2.69 per share.
Please see the attached notification form for further information.
Jon Olav Ødegård, CEO of Hofseth BioCare ASA
Phone: +47 936 32 966
E-mail: joo@hofsethbiocare.no
This information is subject to the disclosure requirements in the Market Abuse
Regulation EU 596/2014 article 19 number 3 and the Norwegian Securities Trading
Act section 5-12.